Neuphoria Therapeutics (NEUP) Total Current Liabilities (2021 - 2026)

Neuphoria Therapeutics (NEUP) has 6 years of Total Current Liabilities data on file, last reported at $1.5 million in Q1 2026.

• Quarterly Total Current Liabilities fell 2.5% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 2.5% YoY) and the FY2025 annual result came in at $4.2 million, up 10.23% from the prior year.
• Total Current Liabilities fell to $1.5 million in Q1 2026 per NEUP's latest filing, from $2.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $5.1 million in Q3 2025 and bottomed at $1.5 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $2.6 million (2024), against an average of $2.9 million.
• The widest annual swing landed in 2025, when Total Current Liabilities soared 100.82%; it then fell 2.5% in 2026.
• Tracing NEUP's Total Current Liabilities over 5 years: stood at $2.4 million in 2022, then increased by 14.83% to $2.8 million in 2023, then decreased by 22.69% to $2.1 million in 2024, then advanced by 21.21% to $2.6 million in 2025, then sank by 41.49% to $1.5 million in 2026.
• Per Business Quant, the three latest NEUP Total Current Liabilities figures stand at $1.5 million (Q1 2026), $2.6 million (Q4 2025), and $5.1 million (Q3 2025).

Peer Comparison